HighGravityDataEli Lilly — May 1, 2025 release
Fiscal 2025 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000059478-25-000129
Showing in the filing
Revenue
“between $58.0 billion and $61.0 billion”
Period
FY2025
Measure
GAAP-tied
Source
Prose
All guidance in this release · 12
Revenue for FY2025
“between $58.0 billion and $61.0 billion”
Performance margin, reported basis for FY2025
“40.5% and 42.5%”
Performance margin, non-GAAP basis for FY2025
“41.5% and 43.5%”
Other income (expense), reported basis for FY2025
“$850 million to $750 million”
Other income (expense), non-GAAP basis for FY2025
“$700 million to $600 million”
EPS, non-GAAP basis for FY2025
“$20.78 to $22.28”
Earnings per share (reported) for FY2025
“$20.17 to $21.67”
EPS, reported basis for FY2025
“$20.17 to $21.67”
Earnings per share (non-GAAP) for FY2025
“$20.78 to $22.28”
Performance Margin (4) (non-GAAP) for FY2025
“Unchanged”
Other Income/(Expense) (non-GAAP) for FY2025
“Unchanged”
Estimated effective tax rate for FY2025
“17%”
Exhibit 99.1 · the passage around this item
… earlier in the release
• Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials. • Q1 2025 EPS increased 23% to $3.06 on a reported basis and increased 29% to $3.34 on a non-GAAP basis, both inclusive of $1.72 of acquired IPR&D charges. • Revenue guidance reaffirmed to be between $58.0 billion and $61.0 billion. INDIANAPOLIS, May 1, 2025 - Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025. "Lilly had a solid start to the year, with 45% year-over-year revenue growth driven by strong sales of Mounjaro and Zepbound,” said David A. Ricks, Lilly chair and CEO. “Our pipeline continued to deliver across key therapeutic areas, with product approvals in oncology and immunology, and the exciting success of our oral incretin, orforglipron, in the first of seven late-stage studies in diabetes and obesity. To support global demand for our newest medicines, we’re accelerating our manufacturing investments, as underscored by our recent announcement to build four new facilities." Eli Lilly and Company | Lilly Corporate Center | Indianapolis, Indiana 46285 | U.S.A. Financial Results $ in millions, except per share data First-Quarter 2025 2024 % Change Revenue $ 12,728.5 $ 8,768.0 45% Net income – Reported 2,759.3 2,242.9 23% Earnings per share – Reported 3.06 2.48 23% Net income – Non-GAAP 3,004.4 2,335.3 29% Earnings per share – Non-GAAP 3.34 2.58 29% A discussion of the non-GAAP financial measures is included below under "Reconciliation of G
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.